Friday, March 29, 2019 11:31:26 AM
From Toutain's linkedin profile:
Experience
Anavex Life Sciences
SVP Operations
Company NameAnavex Life Sciences
Dates EmployedMar 2018 – Present
Employment Duration1 yr
LocationGreater New York City Area
Targeted Cancer Therapeutics
Member Board of Directors
Company NameTargeted Cancer Therapeutics
Dates EmployedSep 2013 – Present
Employment Duration5 yrs 6 mos
LocationSanta Rosa, CA
Interleukin Genetics
Chief Commercial Officer
Company NameInterleukin Genetics
Dates EmployedJul 2016 – Aug 2017
Employment Duration1 yr 2 mos
LocationWaltham, MA
Biotech Consultant
Executive Consultant
Company NameBiotech Consultant
Dates Employed2015 – 2016
Employment Duration1 yr
LocationCambridge/ Boston Area, MA
• Implement launch of US expanded access program and global EAPs for a phase III company
• Develop US launch and market access plan for a neurology company
• Run early global pricing analysis for a phase I/II biotech
• Develop fundraising plan for a pre-clinical biotech company
• Built early commercial strategy and access for a phase IIb biotech
Sarepta Therapeutics
Head of Global Commercial Development
Company NameSarepta Therapeutics
Dates Employed2014 – 2015
Employment Duration1 yr
LocationCambridge, MA
Alexion Pharmaceuticals
Company NameAlexion Pharmaceuticals
Total Duration4 yrs
TitleGeneral Manager, Switzerland/CEE/CIS Region
Dates Employed2011 – 2013
Employment Duration2 yrs
LocationLausanne Area, Switzerland
TitleSr. Director Global Business Council
Dates Employed2009 – 2011
Employment Duration2 yrs
LocationGreater New York City Area
Celgene Corp.
Sr. Product Manager
Company NameCelgene Corp.
Dates Employed2006 – 2009
Employment Duration3 yrs
LocationGreater New York City Area
Alexion Pharmaceuticals
Associate Dir. Marketing, CRM, Marketing Research
Company NameAlexion Pharmaceuticals
Dates Employed2002 – 2006
Employment Duration4 yrs
LocationGreater New York City Area
Johnson & Johnson
Marketing Manager - Europe
Company NameJohnson & Johnson
Dates Employed1999 – 2001
Employment Duration2 yrs
LocationHamburg Area, Germany
https://www.linkedin.com/in/stephan-toutain/
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM

